iDFS Benefit with Ribociclib Plus Nonsteroidal Aromatase Inhibitor in Patients with HR-positive, HER2-negative Early Breast Cancer By Ogkologos - November 14, 2024 825 0 Facebook Twitter Google+ Pinterest WhatsApp Final invasive disease-free survival results from the NATALEE study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR How the history of medicine influenced our perception of cancer October 13, 2022 COVID-19 Vaccine Myth Busters January 28, 2021 Vegetarian Recipes September 4, 2020 Oral Sunvozertinib Prolongs PFS Over Chemotherapy as First-Line Treatment for Patients... June 23, 2026 Load more HOT NEWS Elderly Woman Seeks Trick-Or-Treaters Who Surprised Her With Gifts The Day... Some Children with Liver Cancer May Need Less Chemotherapy, Study Suggests Adding Capivasertib to Fulvestrant Results in Longer PFS in Patients with... Veteran Dresses As Captain America & Brings Joy To Children In...
